Abstract: The invention relates to triazole compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

Abstract: The invention relates to triazole compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

Abstract: The invention relates to triazole compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

Abstract: Disclosed are chemical entities which are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Formula (I) has the structure, R1a, R1b, R2, R3, R4a, R4b and Y are as defined herein. These chemical entities are useful for reduction of very long chain fatty acid levels. These chemical entities and pharmaceutically acceptable compositions comprising such chemical entities can be useful for treating various diseases, disorders and conditions, such as adrenoleukodystrophy (ALD).

Abstract: The invention relates to triazole compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

Abstract: Disclosed herein are systems and methods for the developing of immuno-stained biological samples. The systems disclosed herein are automated and are configured to control one or more steps of the developing procedure. Reagents may be added using automatic syringe dispensing. Reagent temperature, reagent stirring, and wash procedures are programmable and can be separately controlled for separate immuno-staining procedures that are performed at the same time.

Abstract: Disclosed herein are apparatuses and methods handling a portion of a tissue sample when sectioned by a microtome. The apparatuses include a container, a tissue sample holder in the container, and one or more outlets configured to allow flow of a fluid from the container. the flow through the outlet causes a portion of the tissue sample sectioned by a microtome to move into the outlet. The methods include sectioning one or more portions of a tissue sample, and flowing a fluid past the tissue sample to cause the one or more portions of the tissue sample to move away from the tissue sample and toward at least one fluid outlet.

Abstract: Apparatuses and methods for handling a portion of a tissue sample when sectioned by a microtome. The apparatuses include a container, a tissue sample holder in the container, and one or more outlets configured to allow flow of a fluid from the container. The flow through the outlet causes a portion of the tissue sample sectioned by a microtome to move into the outlet. The methods include sectioning one or more portions of a tissue sample, and flowing a fluid past the tissue sample to cause the one or more portions of the tissue sample to move away from the tissue sample and toward at least one fluid outlet.

Abstract: Disclosed herein are systems and methods for the developing of immuno-stained biological samples. The systems disclosed herein are automated and are configured to control one or more steps of the developing procedure. Reagents may be added using automatic syringe dispensing. Reagent temperature, reagent stirring, and wash procedures are programmable and can be separately controlled for separate immuno-staining procedures that are performed at the same time.

Abstract: Disclosed herein are systems and methods for the developing of immuno-stained biological samples. The systems disclosed herein are automated and are configured to control one or more steps of the developing procedure. Reagents may be added using automatic syringe dispensing. Reagent temperature, reagent stirring, and wash procedures are programmable and can be separately controlled for separate immuno-staining procedures that are performed at the same time.

Abstract: Disclosed herein are apparatuses and methods handling a portion of a tissue sample when sectioned by a microtome. The apparatuses include a container, a tissue sample holder in the container, and one or more outlets configured to allow flow of a fluid from the container. the flow through the outlet causes a portion of the tissue sample sectioned by a microtome to move into the outlet. The methods include sectioning one or more portions of a tissue sample, and flowing a fluid past the tissue sample to cause the one or more portions of the tissue sample to move away from the tissue sample and toward at least one fluid outlet.